This activity is hosted on the site of our educational partner
You will be connecting to our educational partner, which controls its own content, practices, and other policies.
You will be connecting to our educational partner, which controls its own content, practices, and other policies.
Advancing the Care of Patients with SSc-ILD: Accurate Diagnosis, Improved Risk Assessment, and Evidence-based Disease Management
Powered by
Format
Webcast
Time to Complete
1 hour
Released
December 5, 2018
Expires
December 5, 2019
Maximum Credits
1.00 / AMA PRA Category 1 CreditTM
Accredited Provider
Provided by Integrity Continuing Education
Commercial Supporter
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Program Description
Interstitial lung disease (ILD) is the most serious complication of systemic sclerosis (SSc), with patients subject to pulmonary fibrosis that causes a progressive decline in lung function and, in many cases, leads to respiratory failure. Despite increasing disease awareness, prompt and accurate diagnosis remains challenging due to the lack of accepted protocols for screening and risk stratification, as well as difficulties in distinguishing between systemic manifestations of SSc and exertional dyspnea due to lung involvement. Traditional treatment approaches have centered upon immunosuppression to target underlying inflammation and autoimmunity. However, with the advent of antifibrotic therapies capable of slowing, or even halting, the progression of idiopathic pulmonary fibrosis, questions have been raised about their potential to similarly impact SSc-ILD progression. This program will provide clinicians with education that is targeted at helping them to remain informed regarding the current status of these investigations, as well as provide them with the knowledge and skills to provide patients with SSc-ILD with an accurate diagnosis and optimal disease management.
Intended Audience
This educational initiative has been designed for pulmonologists, rheumatologists, and internal medicine physicians involved in the care of patients with SSc-ILD.
Educational Objectives
Upon completion of this educational activity, participants should be able to:
- Describe the components of an appropriate multidisciplinary workup for the differential diagnosis and staging of SSc-ILD
- Apply an individualized approach to SSc-ILD treatment that is consistent with current clinical trial evidence and consensus guidelines
- Identify communication strategies for promoting disease understanding and shared decision-making among patients with SSc-ILD, as well as collaboration across the multidisciplinary care team
Conflict Of Interest Disclosure Policy
Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Integrity Continuing Education is committed to providing learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest or a commercial interest.
The faculty/planners reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity.
The faculty/planners reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity.
Faculty
Aryeh Fischer, MD
Associate Professor of Medicine
Division of Rheumatology
Division of Pulmonary Sciences & Critical Care Medicine
Department of Medicine
University of Colorado School of Medicine
Aurora, Colorado
Dr. Fischer discloses the following:
Consulting Fees: Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffman-La Roche Ltd
Kevin Flaherty, MD, MS
Professor of Internal Medicine
Division of Pulmonary & Critical Care Medicine
University of Michigan
Ann Arbor, Michigan
Dr. Flaherty discloses the following:
Consulting Fees: Boehringer Ingelheim Pharmaceuticals, Inc., Celgene Corporation, Genentech, Inc., Sanofi Genzyme, Veracyte, Inc.
Contracted Research (paid to university): Boehringer Ingelheim Pharmaceuticals, Inc., Genentech, Inc.
Royalty: UpToDate® (Wolters Kluwer)
Lisa H Lancaster, MD
Medical Director
Interstitial Lung Disease Program
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee
Dr. Lancaster discloses the following:
Consulting Fees: Bellerophon Therapeutics, Boehringer Ingelheim Pharmaceuticals, Inc., Genentech, Inc.
Contracted Research: Boehringer Ingelheim Pharmaceuticals, Inc., Celgene Corporation, Genentech, Inc., Novartis Pharmaceuticals Corporation
Associate Professor of Medicine
Division of Rheumatology
Division of Pulmonary Sciences & Critical Care Medicine
Department of Medicine
University of Colorado School of Medicine
Aurora, Colorado
Dr. Fischer discloses the following:
Consulting Fees: Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffman-La Roche Ltd
Kevin Flaherty, MD, MS
Professor of Internal Medicine
Division of Pulmonary & Critical Care Medicine
University of Michigan
Ann Arbor, Michigan
Dr. Flaherty discloses the following:
Consulting Fees: Boehringer Ingelheim Pharmaceuticals, Inc., Celgene Corporation, Genentech, Inc., Sanofi Genzyme, Veracyte, Inc.
Contracted Research (paid to university): Boehringer Ingelheim Pharmaceuticals, Inc., Genentech, Inc.
Royalty: UpToDate® (Wolters Kluwer)
Lisa H Lancaster, MD
Medical Director
Interstitial Lung Disease Program
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee
Dr. Lancaster discloses the following:
Consulting Fees: Bellerophon Therapeutics, Boehringer Ingelheim Pharmaceuticals, Inc., Genentech, Inc.
Contracted Research: Boehringer Ingelheim Pharmaceuticals, Inc., Celgene Corporation, Genentech, Inc., Novartis Pharmaceuticals Corporation
Accredited Provider Disclosure
The following planner and manager, Michelle R. Rizzo, ELS, hereby states that she or her spouse/ life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Credit
1.00
Type
AMA PRA Category 1 Credit(s)TM
Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integrity Continuing Education and Boehringer Ingelheim Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education and Boehringer Ingelheim, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education and Boehringer Ingelheim, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Instructions
There are no fees for participating and receiving CME credit for this activity. During the period of December 5, 2018 through December 5, 2019, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pre-test
- Study the educational activity
- Complete the post-test and the evaluation form
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc., at (855) 835-4004 or information@integrityce.com.
If you have any questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.
Privacy Policy
SYSTEM REQUIREMENTS
Hardware and Software Requirements
- A computer with an internet connection
- Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
- Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required